Skip to main content

In vitro studies in the development of monoclonal antibodies (mAbs)

In vitro studies are essential in the development of monoclonal antibodies (mAbs) like nivolumab, a checkpoint inhibitor targeting the PD-1 (programmed cell death protein-1) receptor. These studies aim to elucidate various pharmacological and biophysical properties before moving into animal and human studies. Here’s how in vitro studies are applied in the development of nivolumab and similar mAbs:

1. Target Binding and Affinity Assessment

  • Binding Assays: Surface plasmon resonance (SPR) and enzyme-linked immunosorbent assays (ELISA) are common techniques used to determine the binding kinetics of nivolumab to PD-1. These studies establish the binding affinity (Kd), association, and dissociation rates of nivolumab to its target.
  • Epitope Mapping: Epitope mapping identifies the specific PD-1 region that nivolumab binds. It’s crucial for understanding potential competition with natural PD-1 ligands (PD-L1 and PD-L2) and predicting immunogenicity.

2. Mechanism of Action Studies

  • Cell-Based Functional Assays: The PD-1 pathway inhibits T-cell activation. In vitro assays using T-cells or Jurkat cells engineered to express PD-1 can assess nivolumab’s ability to block this pathway. Cytokine release assays measure IFN-γ and IL-2 levels as indicators of T-cell activation after nivolumab treatment.
  • Receptor Occupancy Assays: Flow cytometry is often used to assess nivolumab's binding to PD-1 on immune cells and the degree of receptor occupancy at different concentrations. This informs dosing and expected efficacy in vivo.

3. Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC)

  • ADCC Assays: Although nivolumab's primary mechanism is immune checkpoint inhibition, ADCC and CDC assays test its potential to mediate cell killing via Fcγ receptors on immune effector cells or the complement cascade. For nivolumab, these are usually less relevant due to its IgG4 backbone, which minimizes effector functions to reduce off-target effects.

4. Pharmacokinetics and Stability Studies

  • FcRn Binding Assays: The neonatal Fc receptor (FcRn) plays a key role in extending mAb half-life by protecting it from lysosomal degradation. In vitro binding assays to FcRn, particularly at acidic pH, evaluate nivolumab’s likelihood of recycling and a prolonged half-life in circulation.
  • Thermal and Chemical Stability Testing: Differential scanning calorimetry (DSC) and other stability assays assess nivolumab's structural stability under various temperatures and pH conditions. These tests are essential for formulation development and ensuring stability during storage and administration.

5. Anti-Drug Antibody (ADA) Evaluation

  • ADA Assays: In vitro ADA assays predict the likelihood of immunogenic responses to nivolumab. These involve exposing immune cells to nivolumab and measuring the production of anti-drug antibodies using assays like bridging ELISAs or electrochemiluminescence assays.

6. Off-Target Binding and Toxicity

  • Cross-Reactivity Studies: These studies assess whether nivolumab binds non-specifically to other cell types or receptors, reducing potential adverse effects. Immunohistochemistry or flow cytometry methods can determine binding specificity across various tissue types.
  • Cytotoxicity Testing: Even though nivolumab is engineered to be non-cytotoxic, assays that monitor apoptosis or necrosis in non-target cells confirm its specificity and safety.

7. In Vitro-to-In Vivo Correlation (IVIVC)

  • PK/PD Modeling: In vitro data on nivolumab's binding kinetics, receptor occupancy, and cellular response guide the development of PK/PD models. These models predict how nivolumab behaves in vivo, helping to estimate dosing and efficacy in human trials.

Summary

In vitro studies for nivolumab focus on confirming PD-1 binding and inhibition, ensuring safety through reduced Fc effector function, and assessing stability and immunogenicity. These early-stage evaluations are crucial for determining dosing, mechanism of action, and potential adverse effects, ensuring that only well-characterized and promising candidates advance to clinical trials.

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more